Sales growth at German pharmaceutical company Beiersdorf in 1994 came mainly from outside Germany. Group sales were ahead 8.2% to 5.1 billion Deutschemarks ($3.6 billion). Of this, sales outside Germany were around 3.2 billion marks, up 10.2%, representing 64% of the total. Domestic sales were around 1.8 billion marks, up 4.8%.
Group net profits in 1994 were 207.8 million marks, advancing 15.8%. Earnings per share were up 13.8% to 47.9 marks. The company said that profits grew faster than sales during the year, which was considered to be a "successful" one because of "restrained" increases in material and personnel costs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze